Medicenna to Unveil Preclinical Data for Tumor-Targeted Immunotherapy at AACR 2026
Event summary
- Medicenna will present preclinical data for MDNA113, a first-in-class tumor-targeted anti-PD-1-IL-2 bifunctional superkine, at the AACR Annual Meeting 2026 on April 21.
- MDNA113 is designed to selectively deliver anti-PD-1 and IL-2 to the tumor microenvironment, targeting IL-13Rα2 overexpressed in immunologically cold tumors.
- Preclinical data highlights exceptional selectivity, localization, and potency in the tumor microenvironment, with enhanced systemic tolerability.
- Non-human primate studies show differentiated safety and immunodynamic profiles for MDNA113.
- Medicenna plans to submit an IND application for MDNA113 in the second half of 2026.
The big picture
Medicenna's presentation at AACR 2026 underscores the growing focus on targeted immunotherapies for immunologically cold tumors, which have historically been challenging to treat. The company's proprietary platforms, BiSKITs and T-MASK, aim to overcome limitations of existing therapies by enhancing selectivity and reducing systemic toxicity. Success in this area could expand treatment options for over 2 million patients annually affected by pancreatic, liver, brain, breast, colon, ovarian, and prostate cancers.
What we're watching
- Regulatory Milestones
- The pace at which Medicenna advances MDNA113 toward IND submission and subsequent clinical trials will determine its competitive positioning in the immunotherapy space.
- Clinical Efficacy
- Whether MDNA113's preclinical promise translates into clinical efficacy, particularly in immunologically cold tumors with high unmet needs.
- Market Differentiation
- How Medicenna's BiSKITs and T-MASK platforms will differentiate MDNA113 from competing immunotherapy programs in terms of safety and therapeutic window.
Related topics